HC Wainwright Comments on ALX Oncology FY2029 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of ALX Oncology in a report issued on Friday, January 24th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of $0.63 per share for the year. HC Wainwright currently has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

A number of other equities analysts also recently issued reports on the stock. Jefferies Financial Group downgraded shares of ALX Oncology from a “buy” rating to a “hold” rating and cut their price objective for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Friday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $3.50.

ALX Oncology Price Performance

Shares of ALXO opened at $1.52 on Monday. The stock has a market cap of $79.91 million, a P/E ratio of -0.51 and a beta of 0.98. The business’s fifty day moving average is $1.62 and its 200 day moving average is $2.36. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a 12-month low of $1.19 and a 12-month high of $17.83.

Insider Activity

In other news, Director Rekha Hemrajani bought 30,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the purchase, the director now directly owns 33,000 shares in the company, valued at $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 14,443 shares of company stock worth $23,309 over the last ninety days. Company insiders own 33.40% of the company’s stock.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in ALX Oncology by 243.6% in the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after buying an additional 42,185 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of ALX Oncology during the third quarter valued at approximately $578,000. Wellington Management Group LLP boosted its stake in shares of ALX Oncology by 15.2% during the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after purchasing an additional 22,114 shares during the period. Verition Fund Management LLC boosted its stake in shares of ALX Oncology by 308.4% during the third quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock valued at $242,000 after purchasing an additional 100,454 shares during the period. Finally, Walleye Capital LLC lifted its stake in ALX Oncology by 110.3% in the third quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock worth $420,000 after acquiring an additional 121,113 shares during the period. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.